Table 3 Objective response rate (ORR) and disease control rate (DCR) by pretreatment serum levels of hepatocyte growth factor (HGF) and epiregulin (EREG) when the cutoff values are median of serum concentration
| Â | Â | Pretreatment HGF level (cutoff value: median) | Pretreatment EREG level (cutoff value: median) | ||||
|---|---|---|---|---|---|---|---|
Response | A total patients | High | Low | P -value | High | Low | P -value |
A | |||||||
PR | 34 (33.0%) | 16 (30.8%) | 18 (35.3%) | Â | 11 (21.6%) | 23 (44.2%) | Â |
SD | 37 (35.9%) | 15 (28.8%) | 22 (43.1%) | Â | 18 (35.3%) | 19 (36.5%) | Â |
PD | 32 (31.1%) | 21 (40.4%) | 11 (21.6%) | Â | 22 (43.1%) | 10 (19.2%) | Â |
ORR (95% CI) | 33.0% (24.1–43.0) | 30.8% (18.7–45.1) | 35.3% (22.4–49.9) | 0.678 | 23.5% (12.8–37.5) | 40.4% (27.0–54.9) | 0.091 |
DCR (95%CI) | 68.9% (59.1–77.7) | 59.6% (45.1–73.1) | 78.4% (64.7–88.7) | 0.055 | 58.8% (44.2–72.4) | 76.9% (63.2–87.5) | 0.059 |
B | |||||||
PR | 24 (42.1%) | 9 (31.0%) | 15 (53.6%) | Â | 7 (25.9%) | 17 (56.6%) | Â |
SD | 22 (38.6%) | 12 (41.4%) | 10 (35.7%) | Â | 11 (40.7%) | 11 (36.7%) | Â |
PD | 11 (19.3%) | 8 (27.6%) | 3 (10.7%) | Â | 9 (33.3%) | 2 (6.7%) | Â |
ORR (95% CI) | 42.1% (29.1–55.9) | 31.0% (15.3–50.8) | 53.6% (33.9–72.5) | 0.110 | 25.9% (11.1–46.3) | 56.6% (37.4–74.5) | 0.031 |
DCR (95%CI) | 80.7% (68.1–90.9) | 72.4% (52.8–87.3) | 78.4% (71.8–97.7) | 0.179 | 66.6% (46.0–83.5) | 93.3% (77.9–99.2) | 0.017 |
